Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanosonics Limited ( (AU:NAN) ) has shared an update.
Nanosonics reported half-year revenue of $102.2 million for the period ended 31 December 2025, a 9% increase on the prior corresponding period, reflecting continued sales growth across its infection prevention portfolio. However, profit before tax edged down 3% to $10.6 million and net profit after tax dipped 1% to $9.6 million, with basic earnings per share easing 2% to 3.17 cents.
The company’s net tangible assets per share rose 18.5% to 66.22 cents, indicating a stronger balance sheet despite the modest profit decline. Nanosonics did not declare a dividend for the half-year, consistent with the prior period, and confirmed there were no changes in control of entities, associates or joint ventures, underscoring a stable corporate structure as it continues to apply international reporting standards across its global subsidiaries.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is a medical technology company focused on infection prevention solutions for healthcare settings. Through its network of wholly owned subsidiaries in Europe, North America and Asia, the group develops and commercialises products designed to improve disinfection standards and patient safety in hospitals and clinics.
YTD Price Performance: -5.04%
Average Trading Volume: 411,916
Technical Sentiment Signal: Sell
Current Market Cap: A$1.09B
For detailed information about NAN stock, go to TipRanks’ Stock Analysis page.